- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT05991882
Mobile Intervention for Simultaneous Alcohol and Marijuana Use in Young Adults (SAFERR)
Mobile Adaptive Intervention to Reduce Negative Consequences Associated with Simultaneous Alcohol and Marijuana Use in Young Adults in Primary Care
Study Overview
Status
Conditions
Intervention / Treatment
- Behavioral: Condition 1: Craving daily+PBS daily
- Behavioral: Condition 2: Craving daily+PBS trigger
- Behavioral: Condition 3: Craving trigger+PBS daily
- Behavioral: Condition 4: Craving trigger+PBS trigger
- Behavioral: Condition 5: PBS daily+ PBS trigger
- Behavioral: Condition 6: Craving daily+Craving trigger
- Behavioral: Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger
- Behavioral: Condition 8: No daily or trigger craving or PBS
Detailed Description
Up to one-third of young adults report use of marijuana or alcohol in the past month, with sizable numbers reporting daily marijuana use and heavy episodic drinking. Simultaneous alcohol and marijuana (SAM) use, defined as use of both substances at the same time or within a few hours of each other with overlapping effects, is common among young adults. Recent research has shown that SAM use leads to greater negative consequences compared to use of either substance alone. No current intervention addresses SAM use specifically and few leverage new technological methods (e.g., smartphones) or strategies (e.g., protective behavioral strategies [PBS]) to engage young adults.
The goal of this Stage I treatment development project is to develop a fully mobile adaptive ecological momentary intervention (a-EMI) titled "Smartphone App For Effectively Reducing Risk (SAFERR)" that is grounded in self-regulation and social cognitive theories. To determine the most efficacious intervention strategies, the investigators will test variations of intervention components to identify the best combination. They will assess the feasibility and efficacy of intervention components on two outcomes (negative consequences and PBS) using a fractional factorial experimental design.
The study will take place at the Center for Integrated Health Care Research at Kaiser Permanente Hawaii (KPHI), located in Honolulu (island of Oahu). Following pilot testing, the SAFERR a-EMI will be administered to 6 eligible participants. Based on the feedback, the app will be revised and a trial of the SAFERR intervention will begin. 136 diverse young adults who report current SAM use will be recruited from primary care clinics at KPHI. Eligible individuals will complete a baseline assessment and then be randomly assigned (by sex) to one of eight conditions using stratified randomization. Each condition either includes or does not include four different intervention strategies focused on craving reduction and PBS. All participants will complete signal-contingent (random prompts three times per day) and event-related ecological momentary assessment (EMA) for 6 weeks using a smartphone application (app). EMA will continue during the 4-week intervention phase. At the beginning of the intervention, all participants will complete an introduction module via the study app that includes psychoeducation, personalized feedback, and goal setting. Participants will then begin the a-EMI via the study app, with components delivered based on their condition assignment.
Following completion of the intervention, participants will complete a post-intervention assessment and follow-up assessments at one- and three-months. The feasibility of the a-EMI and design will be examined by assessing: study attrition and response rates/time, module completion rates, acceptability (satisfaction, usability), perceived helpfulness, goal attainment, and implementation and intervention engagement. The efficacy of intervention components on negative consequences and PBS during EMA and at post-intervention and one-month and three-month follow-ups will be examined. In a future, larger study, the most useful components will be incorporated into a full intervention package and tested in a randomized controlled trial.
Study Type
Enrollment (Estimated)
Phase
- Not Applicable
Contacts and Locations
Study Contact
- Name: Kristina Phillips, PhD
- Phone Number: 808-432-4687
- Email: kristina.t.phillips@kp.org
Study Contact Backup
- Name: Kara Tsuzaki, PharmD
- Phone Number: 1466 808-432-5500
- Email: kara.k.tsuzaki@kp.org
Study Locations
-
-
Hawaii
-
Honolulu, Hawaii, United States, 96815
- Recruiting
- Kaiser Permanente Hawaii, Center for Integrated Health Care Research
-
Contact:
- Kristina Phillips, PhD
- Phone Number: 808-432-4687
- Email: kristina.t.phillips@kp.org
-
Contact:
- Kara Tsuzaki, PharmD
- Phone Number: 808-272-5276
- Email: kara.k.tsuzaki@kp.org
-
Contact:
- Kristina Phillips, PhD
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
- Adult
Accepts Healthy Volunteers
Description
Inclusion Criteria:
- resident of state of Hawai'i and island of O'ahu
- age 18-30 years
- has sought services at Kaiser Permanente Hawaii within the past year
- report marijuana use, heavy drinking, and simultaneous alcohol and marijuana use
- report confidence in ability to use protective behavioral strategies
- endorse at least 3 recent negative consequences from marijuana and/or alcohol
- own a smartphone
Exclusion Criteria:
• any substance use treatment within the past 3 months
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Factorial Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
Experimental: Condition 1: Craving daily+PBS daily
EMA + Introduction Module + Craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily
|
Participants in this condition will complete ecological momentary assessment (EMA) for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction and protective behavioral strategy (PBS) messages, each delivered once daily, until the end of the six-week period.
|
|
Experimental: Condition 2: Craving daily+PBS trigger
EMA + Introduction Module + Craving reduction messages delivered once daily and PBS trigger messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
|
|
Experimental: Condition 3: Craving trigger+PBS daily
EMA + Introduction Module + Craving reduction trigger messages and PBS messages delivered once daily
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction messages that will be delivered based on responses to signal-contingent EMA questions and PBS delivered once daily.
|
|
Experimental: Condition 4: Craving trigger+PBS trigger
EMA + Introduction Module + Craving reduction trigger and PBS trigger messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction and PBS messages delivered based on responses to signal-contingent EMA questions.
|
|
Experimental: Condition 5: PBS daily+ PBS trigger
EMA + Introduction Module + PBS delivered once daily and PBS trigger messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive PBS messages delivered once daily and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
|
|
Experimental: Condition 6: Craving daily+Craving trigger
EMA + Introduction Module + Craving reduction delivered once daily and craving reduction trigger messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction messages delivered once daily and craving reduction trigger messages that will be based on responses to signal-contingent EMA questions.
|
|
Experimental: Condition 7: Craving daily+Craving trigger+PBS daily+PBS trigger
EMA + Introduction Module + Craving reduction delivered once daily, craving reduction trigger messages, PBS delivered once daily, and PBS trigger messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will then receive craving reduction and PBS messages delivered once daily and non-repetitive craving reduction and PBS trigger messages that will be based on responses to signal-contingent EMA questions.
|
|
Other: Condition 8: No daily or trigger craving or PBS
EMA + Introduction Module + no other messages
|
Participants in this condition will complete EMA for six weeks.
Following the initial two weeks of EMA, participants in this condition will complete an introduction module including psychoeducation, personalized feedback, and goal setting.
Participants will not receive any further intervention strategies.
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Negative consequences associated with alcohol, marijuana, and simultaneous alcohol and marijuana (SAM) use
Time Frame: Through study completion, an average of 5 months
|
Changes in negative consequences will be assessed using a measure that assesses alcohol, marijuana, and SAM use negative consequences.
Items are rated dichotomously (yes/no).
|
Through study completion, an average of 5 months
|
|
Protective behavioral strategies for alcohol
Time Frame: Through study completion, an average of 5 months
|
Changes in protective behavioral strategies for alcohol will be assessed using the Protective Drinking Practices Scale (PDPS), which assesses use of protective behavioral strategies related to alcohol on a 1 (never) to 6 (always) scale.
|
Through study completion, an average of 5 months
|
|
Protective behavioral strategies for marijuana
Time Frame: Through study completion, an average of 5 months
|
Changes in protective behavioral strategies for marijuana will be assessed using the Protective Behavioral Strategies for Marijuana (PBSM) Scale, which assesses use of protective behavioral strategies related to marijuana on a 1 (never) to 6 (always) scale.
|
Through study completion, an average of 5 months
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Feasibility - study attrition
Time Frame: Through study completion, an average of 5 months
|
Number of completed study phases, including six weeks of ecological momentary assessment (EMA), the 4-week a-EMI period, post-intervention assessment, and one- and three-month follow-up assessments.
|
Through study completion, an average of 5 months
|
|
Feasibility - response rate
Time Frame: Week 7
|
Number of completed prompts across 6-week EMA
|
Week 7
|
|
Feasibility - module completion rate
Time Frame: Week 7
|
Completion of introduction module focused on psychoeducation, personalized feedback, and goal setting
|
Week 7
|
|
Feasibility - acceptability of the intervention
Time Frame: Week 7
|
The revised Client Satisfaction Questionnaire (CSQ-8) will assess satisfaction with the intervention, perceptions of format and language of the a-EMI messages, and usability of the a-EMI (e.g., manner in which information was presented, language, question/intervention strategy comprehension, strategy delivery, timing, and study and a-EMI burden).
|
Week 7
|
|
Feasibility - perceived helpfulness of intervention strategies
Time Frame: Week 7
|
A Feedback Measure will assess perceptions of the helpfulness of particular intervention strategies, as well as other useful strategies that could be added.
|
Week 7
|
|
Feasibility - intervention implementation
Time Frame: Week 7
|
Intervention implementation will be examined through a short survey that will assess the ease of app use and accessibility, any challenges requesting strategies when needed, and any problems with the technology.
|
Week 7
|
|
Feasibility - intervention engagement
Time Frame: Week 7
|
Intervention engagement will be assessed by examining participant's use of intervention strategies.
|
Week 7
|
|
Feasibility - goal attainment
Time Frame: Through study completion, an average of 5 months
|
Participants will be asked to report whether they attained or made progress on goals identified in the a-EMI introduction module.
|
Through study completion, an average of 5 months
|
Collaborators and Investigators
Sponsor
Collaborators
Investigators
- Principal Investigator: Kristina Phillips, PhD, Kaiser Permanente Hawaii
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Estimated)
Study Completion (Estimated)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- R34DA056759 (U.S. NIH Grant/Contract)
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Alcohol Drinking
-
University of North Carolina, Chapel HillNational Institute on Alcohol Abuse and Alcoholism (NIAAA)CompletedDrinking Behavior | Adolescent Behavior | Drinking, Alcohol | Alcohol Drinking, AdolescentUnited States
-
University of Auckland, New ZealandTe Hiringa Hauora/Health Promotion AgencyCompletedDrinking, Alcohol | Consumption, AlcoholNew Zealand
-
Penn State UniversityNot yet recruiting
-
Boston University Charles River CampusActive, not recruiting
-
Binghamton UniversityNot yet recruitingUnderage Drinking | Drinking, Teen | Adolescent Alcohol UseUnited States
-
Butler HospitalNational Institute of General Medical Sciences (NIGMS)CompletedDrinking, AlcoholUnited States
-
The University of Hong KongRecruitingmHealth Intervention | AlcoholHong Kong
-
Real Prevention, LLCCompletedUnderage Drinking | Alcohol Use, UnderageUnited States
-
Universidad de GranadaCompletedExercise | Drinking, AlcoholSpain
-
University of FloridaNational Institute on Alcohol Abuse and Alcoholism (NIAAA)Completed
Clinical Trials on Condition 1: Craving daily+PBS daily
-
University of Maryland, BaltimoreNot yet recruitingCommunity Acquired Pneumonia (CAP)United States
-
Chang ChenNot yet recruiting
-
Kessler FoundationNational Multiple Sclerosis SocietyCompletedCognitive Impairment in Multiple SclerosisUnited States
-
Spectrum Pharmaceuticals, IncTerminated
-
National Cancer Center, KoreaUnknownLimited Disease Small Cell Lung CancerKorea, Republic of
-
Onorach Clinical LtdCompleted
-
Texas A&M UniversityCompletedCognitive Change | Nutritional Anemia | Diet, Healthy | Nutrient Deficiency | Diet; Deficiency | Visual Spatial Processing | Dietary Deficiency | Dietary B12 Deficiency | Dietary Zinc Deficiency | Dietary Vitamin B12 Deficiency Anemia | Dietary Deficiency of Selenium and Vitamin EUnited States
-
CooperVision, Inc.Completed
-
Bausch & Lomb IncorporatedCompleted
-
Combined Military Hospital AbbottabadNot yet recruiting